RxDoctor Payments Data

Jennifer Normann, MD

Internal Medicine · Sanford, NCNPI 1841291655

Payments from drug & device makers

$5,497in general payments, 2019–2025

Across 295 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$603
  • AbbVie$240
  • Lilly USA, LLC$220
  • Boehringer Ingelheim$202
  • Novartis$176
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,497 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$176,284
Medicare patients
353
Services billed
7,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$225,545
JardianceEmpagliflozin78$65,041
EliquisApixaban61$46,414
MounjaroTirzepatide37$44,583
JanuviaSitagliptin Phosphate33$29,374
XareltoRivaroxaban17$18,040
TrulicityDulaglutide13$13,152
Janumet XrSitagliptin Phos/Metformin Hcl18$9,915
Emgality PenGalcanezumab-Gnlm12$8,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,910
SynthroidLevothyroxine Sodium74$7,519
MyrbetriqMirabegron13$5,691
Bupropion XlBupropion Hcl82$5,356
Levothyroxine Sodium382$4,112
DexilantDexlansoprazole13$3,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,312$225,545168 claims
Boehringer IngelheimJardiance$202$65,04178 claims
Lilly USA, LLCMounjaro, Trulicity$220$57,73550 claims
PfizerEliquis$94$46,41461 claims
MerckJanuvia, Janumet Xr$110$39,28951 claims
GSKTrelegy Ellipta$162$7,91012 claims
AbbVieSynthroid$240$7,51974 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$18$3,80913 claims
AstraZenecaSymbicort$14$2,42111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Sanford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →